Physician profile
Muhammad Khan
NPI 1184091498
$10,110.04
in general payments reported to CMS, 2019-2025
17 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $466 · 2022: $4,155 · 2023: $1,434 · 2024: $3,898 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,093 · Grant: $1,500 · Food and Beverage: $1,480 · Education: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,092.71 |
| Grant | $1,500.00 |
| Food and Beverage | $1,479.87 |
| Education | $416.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,226.23 | 2021-2023 | Diamondback Coronary, Assurity, Gallant |
| Medtronic, INC. | $3,575.98 | 2022-2024 | Corevalve Evolut R, Onyx Frontier |
| Abiomed | $784.93 | 2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $657.52 | 2021-2024 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $155.37 | 2023-2024 | Brilinta, Wainua, Farxiga |
| Boston Scientific Corporation | $153.87 | 2024 | Avvigo Guidance System |
| Penumbra, INC. | $128.81 | 2025 | Indigo System |
| Cathworks, INC. | $84.12 | 2023 | Ffrangio |
| Janssen Pharmaceuticals, INC | $55.64 | 2023-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $54.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $52.45 | 2024 | |
| Route 92 Medical, INC. | $48.57 | 2023 | 8f Base Camp Sheath System |
| Teleflex LLC | $41.82 | 2024 | Manta |
| Sumitomo Pharma America, INC. | $27.95 | 2025 | Gemtesa |
| Kiniksa Pharmaceuticals International, Plc | $24.48 | 2024 | Arcalyst |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $22.51 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $15.00 | 2024 | Vibativ |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.